ZIOPHARM Oncology (ZIOP) Releases Earnings Results, Misses Expectations By $-0.90 EPS

ZIOPHARM Oncology (ZIOP) reported quarterly earnings results on Tuesday, Aug-9-2016. The company reported $-1.01 earnings per share for the quarter, missing the analyst consensus estimate by $-0.90. Analysts had a consensus of $-0.11. The company posted revenue of $1.70 million in the period, compared to analysts expectations of $1.48 million. The company’s revenue was up 525.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.11 EPS.

Many Wall Street Analysts have commented on ZIOPHARM Oncology. Shares were Reiterated by Mizuho on Jul 19, 2016 to “Neutral” and Lowered the Price Target to $ 5 from a previous price target of $7 .ZIOPHARM Oncology was Initiated by Raymond James to “Mkt Perform” on Jun 2, 2016.

ZIOPHARM Oncology closed down -0.25 points or -4.88% at $4.87 with 12,57,172 shares getting traded on Monday. Post opening the session at $5.15, the shares hit an intraday low of $4.855 and an intraday high of $5.16 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

In a different news, on Nov 23, 2015, Caesar J Belbel (COO, CLO, and Secretary) sold 153,333 shares at $12.84 per share price. According to the SEC, on Jun 11, 2015, Francois Lebel (Executive Vice President R&D) sold 50,000 shares at $10.12 per share price. On Jun 5, 2015, Kevin G Lafond (Vice Pres., Treasurer, & CAO) sold 57,500 shares at $9.67 per share price, according to the Form-4 filing with the securities and exchange commission.

ZIOPHARM Oncology Inc. is a biopharmaceutical company. The Company is engaged in the acquisition development and commercialization of a portfolio of cancer therapies through synthetic biology. The Company’s pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies. The Company’s clinical stage product candidate Ad-RTS-IL-12 is used with the oral activator veledimex being developed for the treatment of oncology. Ad-RTS-IL-12 in combination with veledimex uses the synthetic biology platform (gene-delivery system) to produce Interleukin-12 or IL-12 a potent naturally occurring anti-cancer protein. The Company has completed two Phase II studies evaluating Ad-RTS-IL-12 in combination with veledimex for the treatment of metastatic melanoma and for the treatment of metastatic breast cancer. The Company is also developing CAR-T Cells (Cytokine products).


Leave a Reply

ZIOPHARM Oncology - Is it time to Sell?

Top Brokerage Firms are advising their investors on ZIOPHARM Oncology. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.